Follow-up Prostascint® scans verify detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy

Prostate

Volumn 42, Issue 4, 2000, Pages 315-317

  Murphy, Gerald P ^a   Elgamal, Abdel Aziz A ^a   Troychak, Michael J ^b   Kenny, Gerald M ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b NORTHWEST HOSPITAL   (United States)

Author keywords

ProstaScint ; Prostate cancer; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; INDIUM RADIOISOTOPES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; TREATMENT FAILURE;

EID: 0033981235     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000301)42:4<315::AID-PROS9>3.0.CO;2-S     Document Type: Article

References (18)

1. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint® scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 1998;37:261-269.
2. 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 1991;18:229-241.
3. Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP, Tyson I, Heal A, Mitchell E, Purnell G, Harwood SJ. Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. Semin Urol 1992;10:45-54.
4. Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintography in patients with colorectal, ovarian and prostate cancer. Cancer [Suppl] 1993;72:3453-3462.
5. 111Indiun labeled monoclonal antibody CYT-356. J Urol 1994;152:1952-1955.
6. 111Indiun labeled monoclonal antibody CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994;152:1490-1495.
7. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL. Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostate cancer patients. Prostate 1997;33:281-285.
8. Burgers JK, Hinkle GH, Haseman MK. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 1995;13:103-112.
9. 111-Indium-Capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol 1998;159:2041-2047.
10. Chengazi VU, Feneley MR, Ellison D, Stalteri M, Granowska M, Nimmon CC, Mather SJ, Kirby RS, Britton KE. Imaging prostate cancer with tecnetium-99-m-7E11-C5.3 (CYT-351). J Nucl Med 1997;38:675-682.
11. Hinkle GH, Burgers JK, Olsen JO, Williams BS, Lamartice RA, Barth RF, Rogers B, Maguire RT. Prostate cancer abdominal metastases detected with Indium-111 capromab pendetide. J Nucl Med 1998;39:650-652.
12. Levesque PE, Nieh PT, Zinman LN, Seldin DW, Libertino JA. Radiolabeled monoclonal antibody Indium-111-labeled CYT 365 localizes extraprostatic recurrent carcinoma after prostatectomy. Urology 1998;51:978-984.
13. Sodee DB, Conant R, Chalfant M, Miron S, Klein E, Bahnson R, Spirnak JP, Carlin B, Bellon EM, Rogers B. Preliminary imaging results using In-111 labeled CYT-356 (ProstaScint®) in detection of recurrent prostate cancer. Clin Nucl Med 1996;21:759-767.
14. Ulchaker J, Klein E, Zippe C, Levin H, Neumann D, Ward M. Indium 111 capromab monoclonal antibody: utility in differentiating local versus distant relapse after radical prostatectomy [abstract]. J Urol 1997;157-205.
15. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostate cancer patients. Anticancer Res 1987;7:927-936.
16. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
17. Varkarakis MJ, Murphy GP, Nelson CMK, Chehval M, Moore RH, Flocks RH. Lymph node involvement in prostatic carcinoma. Urol Clin North Am 1975;2:197-212.
18. Saitoh H, Yoshida K-I, Uchijima Y, Kobayashi N, Suwata J, Kamata S. Two different lymph node metastatic patterns of a prostatic cancer. Cancer 1990;65:1843-1846.